MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Sees Large Drop in Short Interest

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) saw a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 669,300 shares, a drop of 13.9% from the July 31st total of 777,300 shares. Based on an average daily trading volume, of 279,700 shares, the days-to-cover ratio is currently 2.4 days. Currently, 3.4% of the company’s shares are short sold.

Institutional Trading of MAIA Biotechnology

Institutional investors have recently added to or reduced their stakes in the business. Ground Swell Capital LLC bought a new position in shares of MAIA Biotechnology in the second quarter valued at approximately $56,000. Mather Group LLC. raised its position in shares of MAIA Biotechnology by 50,150.0% in the second quarter. Mather Group LLC. now owns 12,060 shares of the company’s stock valued at $41,000 after purchasing an additional 12,036 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of MAIA Biotechnology in the first quarter valued at approximately $71,000. 5.65% of the stock is currently owned by institutional investors and hedge funds.

MAIA Biotechnology Stock Performance

Shares of MAIA stock traded up $0.24 during trading on Monday, hitting $3.04. 58,300 shares of the company were exchanged, compared to its average volume of 333,564. The stock has a market cap of $72.69 million, a P/E ratio of -1.92 and a beta of 0.34. MAIA Biotechnology has a twelve month low of $0.82 and a twelve month high of $5.99.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.